haloperidol and Acathisia, Drug-Induced studies

Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.

Research Excerpts

Excerpt	Relevance	Reference
"In adults with schizophrenia or schizoaffective disorder, use of paliperidone palmitate vs haloperidol decanoate did not result in a statistically significant difference in efficacy failure, but was associated with more weight gain and greater increases in serum prolactin, whereas haloperidol decanoate was associated with more akathisia."	9.19	Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. ( Buckley, PF; Byerly, M; Dominik, R; Hamer, RM; Lamberti, JS; McEvoy, JP; Ray, N; Rosenheck, RA; Stroup, TS; Swartz, MS; Wilkins, TM, 2014)
"This randomized, parallel-group, open study investigated the efficacy and safety of risperidone oral solution (RIS-OS) in combination with clonazepam and intramuscular haloperidol for the treatment of acute agitation in patients with schizophrenia, and the study explored the possibility of decreasing the efficacy of an acute 6-week treatment by switching intramuscular haloperidol injection to RIS-OS."	9.16	Comparison of risperidone oral solution and intramuscular haloperidol with the latter shifting to oral therapy for the treatment of acute agitation in patients with schizophrenia. ( Chen, H; Fang, M; Huang, J; Li, LH; Li, Y; Liu, L; Wang, B; Wang, G; Wu, R; Ye, M; Zhang, L; Zhang, Q; Zhao, JP; Zheng, H; Zhou, J; Zhu, S, 2012)
"Asenapine is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with bipolar I disorder with or without psychotic features."	9.14	Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. ( Alphs, L; Cohen, M; Kane, JM; Panagides, J; Zhao, J, 2010)
"To evaluate the effectiveness and cost impact of olanzapine compared with haloperidol in the treatment of schizophrenia."	9.10	Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. ( Allan, E; Bingham, S; Campbell, EC; Caroff, S; Collins, J; Corwin, J; Davis, L; Douyon, R; Dunn, L; Evans, D; Frecska, E; Grabowski, J; Graeber, D; Herz, L; Kwon, K; Lawson, W; Leslie, D; Liu-Mares, W; Mena, F; Perlick, D; Rosenheck, R; Sheikh, J; Smelson, D; Smith-Gamble, V; Warren, S, 2003)
"This randomized double-blind trial was conducted to test the efficacy and safety of olanzapine in Japanese patients with schizophrenia."	9.09	Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: results of the Japan multicenter, double-blind olanzapine trial. ( Inada, T; Ishigooka, J; Miura, S, 2001)
"Pramipexole, a presynaptic dopamine D2/D3 autoreceptor agonist, has been given to haloperidol-treated patients with schizophrenia (n = 15) in an effort to ameliorate residual positive and negative symptoms that have not been satisfactorily influenced by haloperidol alone."	9.08	Pramipexole as adjunct to haloperidol in schizophrenia. Safety and efficacy. ( Barnas, C; Heiden, A; Kasper, S; Laakmann, G; Pfolz, H; Volz, HP; Zeit, H, 1997)
"This multicenter, double-blind, placebo-controlled study evaluated the efficacy and safety of three doses of sertindole (12, 20, and 24 mg/day) and haloperidol (4, 8, and 16 mg/day) in the treatment of psychotic symptoms for 497 hospitalized patients with schizophrenia."	9.08	Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. ( Daniel, DG; Kane, JM; Kashkin, KB; Mack, RJ; Sebree, TB; Tamminga, CA; Wallin, BA; Wozniak, PJ; Zimbroff, DL, 1997)
"The purpose of this study was to compare the efficacy of olanzapine with that of chlorpromazine plus benztropine in patients with treatment-resistant schizophrenia."	9.08	Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. ( Bartko, JJ; Conley, RR; Gounaris, C; Hegerty, J; Lingle, J; Love, R; Peszke, M; Richardson, C; Tamminga, CA; Zaremba, S, 1998)
" This study compared 800 mg/day amisulpride and 20 mg/day haloperidol in patients with acute exacerbations of schizophrenia."	9.08	Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group. ( Boyer, P; Fleurot, O; Möller, HJ; Rein, W, 1997)
"To evaluate the clinical effects of haloperidol for the management of schizophrenia and other similar serious mental illnesses compared with placebo."	8.89	Haloperidol versus placebo for schizophrenia. ( Adams, CE; Bergman, H; Irving, CB; Lawrie, S, 2013)
" The aim of the present study was to analyze on a single case basis the relationship between a sudden increase in suicidality, anxiety symptoms, medication dosing and clinician- and patient-rated akathisia."	6.77	The relationship of Akathisia with treatment emergent suicidality among patients with first-episode schizophrenia treated with haloperidol or risperidone. ( Bauer, M; Doucette, S; Lewitzka, U; Meyer, S; Möller, HJ; Musil, R; Riedel, M; Schennach, R; Seemüller, F, 2012)
"Ongoing haloperidol treatment of 17 schizophrenia patients was supplemented with 1000 mg capsule of omega-3 fatty acids (180 mg EPA+120 mg DHA) bid, vitamin E 400 IU bid and vitamin C 1000 mg/day."	6.73	The impact of omega-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: an open-label pilot study. ( Gursoy, B; Kirli, S; Sarandöl, E; Sipahioglu, D; Sivrioglu, EY, 2007)
"In adults with schizophrenia or schizoaffective disorder, use of paliperidone palmitate vs haloperidol decanoate did not result in a statistically significant difference in efficacy failure, but was associated with more weight gain and greater increases in serum prolactin, whereas haloperidol decanoate was associated with more akathisia."	5.19	Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. ( Buckley, PF; Byerly, M; Dominik, R; Hamer, RM; Lamberti, JS; McEvoy, JP; Ray, N; Rosenheck, RA; Stroup, TS; Swartz, MS; Wilkins, TM, 2014)
"This randomized, parallel-group, open study investigated the efficacy and safety of risperidone oral solution (RIS-OS) in combination with clonazepam and intramuscular haloperidol for the treatment of acute agitation in patients with schizophrenia, and the study explored the possibility of decreasing the efficacy of an acute 6-week treatment by switching intramuscular haloperidol injection to RIS-OS."	5.16	Comparison of risperidone oral solution and intramuscular haloperidol with the latter shifting to oral therapy for the treatment of acute agitation in patients with schizophrenia. ( Chen, H; Fang, M; Huang, J; Li, LH; Li, Y; Liu, L; Wang, B; Wang, G; Wu, R; Ye, M; Zhang, L; Zhang, Q; Zhao, JP; Zheng, H; Zhou, J; Zhu, S, 2012)
"Asenapine is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with bipolar I disorder with or without psychotic features."	5.14	Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. ( Alphs, L; Cohen, M; Kane, JM; Panagides, J; Zhao, J, 2010)
"To evaluate the effectiveness and cost impact of olanzapine compared with haloperidol in the treatment of schizophrenia."	5.10	Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. ( Allan, E; Bingham, S; Campbell, EC; Caroff, S; Collins, J; Corwin, J; Davis, L; Douyon, R; Dunn, L; Evans, D; Frecska, E; Grabowski, J; Graeber, D; Herz, L; Kwon, K; Lawson, W; Leslie, D; Liu-Mares, W; Mena, F; Perlick, D; Rosenheck, R; Sheikh, J; Smelson, D; Smith-Gamble, V; Warren, S, 2003)
"This randomized double-blind trial was conducted to test the efficacy and safety of olanzapine in Japanese patients with schizophrenia."	5.09	Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: results of the Japan multicenter, double-blind olanzapine trial. ( Inada, T; Ishigooka, J; Miura, S, 2001)
"Pramipexole, a presynaptic dopamine D2/D3 autoreceptor agonist, has been given to haloperidol-treated patients with schizophrenia (n = 15) in an effort to ameliorate residual positive and negative symptoms that have not been satisfactorily influenced by haloperidol alone."	5.08	Pramipexole as adjunct to haloperidol in schizophrenia. Safety and efficacy. ( Barnas, C; Heiden, A; Kasper, S; Laakmann, G; Pfolz, H; Volz, HP; Zeit, H, 1997)
"This multicenter, double-blind, placebo-controlled study evaluated the efficacy and safety of three doses of sertindole (12, 20, and 24 mg/day) and haloperidol (4, 8, and 16 mg/day) in the treatment of psychotic symptoms for 497 hospitalized patients with schizophrenia."	5.08	Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. ( Daniel, DG; Kane, JM; Kashkin, KB; Mack, RJ; Sebree, TB; Tamminga, CA; Wallin, BA; Wozniak, PJ; Zimbroff, DL, 1997)
"5 mg/day [Olz-H]) to a dosage range of haloperidol (15 +/- 5 mg/day [Hal]) and to placebo in the treatment of 335 patients who met the DSM-III-R criteria for schizophrenia."	5.08	Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. ( Beasley, CM; Hamilton, S; Sanger, T; Satterlee, W; Tollefson, G; Tran, P, 1996)
" This study compared 800 mg/day amisulpride and 20 mg/day haloperidol in patients with acute exacerbations of schizophrenia."	5.08	Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group. ( Boyer, P; Fleurot, O; Möller, HJ; Rein, W, 1997)
"The purpose of this study was to compare the efficacy of olanzapine with that of chlorpromazine plus benztropine in patients with treatment-resistant schizophrenia."	5.08	Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. ( Bartko, JJ; Conley, RR; Gounaris, C; Hegerty, J; Lingle, J; Love, R; Peszke, M; Richardson, C; Tamminga, CA; Zaremba, S, 1998)
"To evaluate the clinical effects of haloperidol for the management of schizophrenia and other similar serious mental illnesses compared with placebo."	4.89	Haloperidol versus placebo for schizophrenia. ( Adams, CE; Bergman, H; Irving, CB; Lawrie, S, 2013)
" In the Gilles-de-la-Tourette syndrome nicotine reduces the severity and frequency of the tics given in combination with haloperidol."	4.79	[Nicotine in neuropsychiatric movement disorders]. ( Erdmann, R, 1996)
"Clinical safety data for treatment of acute schizophrenia with olanzapine, a new atypical antipsychotic agent, are summarized."	4.79	Safety of olanzapine. ( Beasley, CM; Tollefson, GD; Tran, PV, 1997)
" Efficacy in treating overall psychopathology in acute schizophrenia as measured by the BPRS0-6 total score was demonstrated at 10 mg/day versus placebo; at doses in a 5-20 mg/day range, olanzapine was comparable or superior to haloperidol."	4.79	Dosing the antipsychotic medication olanzapine. ( Nemeroff, CB, 1997)
"Sixty-seven outpatients with schizophrenia receiving stable doses of risperidone or haloperidol were evaluated for akathisia and other extrapyramidal side effects."	3.74	Association of subjective cognitive dysfunction with akathisia in patients receiving stable doses of risperidone or haloperidol. ( Byun, HJ; Kim, JH, 2007)
" But 2 days later he developed auditory hallucinations which were interpreted as alcohol hallucinations, for which he was additionally given haloperidol, 15 mg/d."	3.68	[Central anticholinergic intoxication syndrome. A contribution to the differential diagnosis of exogenous psychoses]. ( Eikmeier, G; Gastpar, M; Kastrup, O, 1991)
"While antipsychotic-induced extrapyramidal symptoms (EPS) and akathisia remain important concerns in the treatment of patients with schizophrenia, the relationship between movement disorder rating scales and spontaneously reported EPS-related adverse events (EPS-AEs) remains unexplored."	2.80	Relating Spontaneously Reported Extrapyramidal Adverse Events to Movement Disorder Rating Scales. ( Fleischhacker, WW; Karayal, ON; Kemmler, G; Kolluri, S; Vanderburg, D; Widschwendter, CG, 2015)
" The aim of the present study was to analyze on a single case basis the relationship between a sudden increase in suicidality, anxiety symptoms, medication dosing and clinician- and patient-rated akathisia."	2.77	The relationship of Akathisia with treatment emergent suicidality among patients with first-episode schizophrenia treated with haloperidol or risperidone. ( Bauer, M; Doucette, S; Lewitzka, U; Meyer, S; Möller, HJ; Musil, R; Riedel, M; Schennach, R; Seemüller, F, 2012)
"Suicidal ideation was significantly associated with clinician observed akathisia, depressed mood, younger age, and use of propranolol."	2.77	Akathisia and suicidal ideation in first-episode schizophrenia. ( Gaebel, W; Gastpar, M; Heuser, I; Jäger, M; Klingenberg, S; Klosterkötter, J; Lewitzka, U; Maier, W; Mayr, A; Möller, HJ; Musil, R; Ohmann, C; Riedel, M; Schennach, R; Schlösser, R; Schmitt, A; Schneider, F; Seemüller, F, 2012)
"Ongoing haloperidol treatment of 17 schizophrenia patients was supplemented with 1000 mg capsule of omega-3 fatty acids (180 mg EPA+120 mg DHA) bid, vitamin E 400 IU bid and vitamin C 1000 mg/day."	2.73	The impact of omega-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: an open-label pilot study. ( Gursoy, B; Kirli, S; Sarandöl, E; Sipahioglu, D; Sivrioglu, EY, 2007)
" The pharmacokinetics of haloperidol and its pharmacodynamic effects measured for QTc prolongation and neurologic side effects were evaluated after a single dose of 5 mg haloperidol following a pretreatment of placebo or itraconazole at 200 mg/d for 10 days in a randomized crossover manner."	2.72	Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects. ( Cha, IJ; Jung, HJ; Kim, KA; Park, JY; Shim, JC; Shin, JG; Shon, JH; Yoon, YR, 2006)
"biperiden was studied in an open clinical trial in twenty-three (12 male and 11 female) patients who developed antipsychotic-induced acute akathisia as defined by the research criteria of the DSM-IV."	2.69	Intravenous biperiden in akathisia: an open pilot study. ( Ashby, CR; Hirose, S, 2000)
"During long-term treatment of schizophrenia with antipsychotic medication, side effects such as weight gain and tardive dyskinesia may develop, while other extrapyramidal side effects may continue."	2.67	Side effects during long-term treatment with depot antipsychotic medication. ( Cookson, JC, 1991)
"We studied the incidence of akathisia in two populations of newly admitted schizophrenic patients: one group was treated with haloperidol and the other group was treated with thiothixene hydrochloride."	2.65	Akathisia with haloperidol and thiothixene. ( Marder, SR; May, PR; Van Putten, T, 1984)
"Patients with delirium are frequently treated with antipsychotic medications that are well known to induce akathisia as a side effect."	2.53	Antipsychotic-induced akathisia in delirium: A systematic review. ( Alici, Y; Forcen, FE; Matsoukas, K, 2016)
"Tardive Tourette syndrome is an extrapyramidal symptom which appears after long-term neuroleptic use."	2.43	[Two cases of tardive Tourette syndrome]. ( Ohmori, T; Yamauchi, K, 2006)
"Most traditional neuroleptics have a narrow therapeutic-to-toxic index, and thus, the novel antipsychotics are the result of a search to substantially widen the distance between the dose that treats psychosis and the one that produces adverse effects."	2.40	The relationship of pharmacology to side effects. ( Casey, DE, 1997)
"Risperidone has these pharmacologic properties."	2.39	Extrapyramidal side effects and tolerability of risperidone: a review. ( Owens, DG, 1994)
"Two patients with akathisia developing only after neuroleptic dosage reduction or withdrawal are described."	2.39	Withdrawal akathisia: case reports and a proposed classification of chronic akathisia. ( Lang, AE, 1994)
"Tardive akathisia is a movement disorder characterized by internal restlessness with an uncontrollable urge to move, leading to repetitive movements."	1.91	Acetaminophen improves tardive akathisia induced by dopamine D ( Kaneko, S; Nagaoka, K; Nagayasu, K; Shirakawa, H, 2023)
"The literature on akathisia in pediatric patients, and especially in patients following acute head injury, is reviewed, with suggestions for an approach to these symptoms in this clinical setting."	1.36	Akathisia after mild traumatic head injury. ( Desai, A; Duhaime, AC; Nierenberg, DW, 2010)
"A 72-year-old man with esophageal cancer who could not sit down or stand up was administered 5 mg/day haloperidol to relieve agitation as a symptom of major depressive disorder."	1.36	Diagnosis and treatment of akathisia in a cancer patient who cannot stand up or sit down, because of poor performance status: factors that make the diagnosis of akathisia difficult, and diagnosis clues. ( Ishida, M; Ito, H; Kawanishi, C; Mizuno, K; Narabayashi, M; Onishi, H; Sasaki, Y; Wada, M; Wada, T, 2010)
" Several animal studies have demonstrated an enhancement of oxidative damage and increased glutamatergic transmission after chronic administration of neuroleptics."	1.34	Protective effect of rutin, a polyphenolic flavonoid against haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes. ( Bishnoi, M; Chopra, K; Kulkarni, SK, 2007)
"Treatment with adenosine or caffeine reversed these behavioural changes."	1.33	Involvement of adenosinergic receptor system in an animal model of tardive dyskinesia and associated behavioural, biochemical and neurochemical changes. ( Bishnoi, M; Chopra, K; Kulkarni, SK, 2006)
"In addition to the diagnosis of chronic pseudoakathisia, five patients (62."	1.31	Prevalence and characteristics of patients with pseudoakathisia. ( Christodoulou, GN; Havaki-Kontaxaki, BJ; Kontaxakis, VP, 2000)
"Haloperidol-treated rats had higher bolus counts than vehicle-treated rats, and this increase was significantly reversed by the lipophilic but not the hydrophilic beta-antagonists."	1.30	The effects of beta-adrenoceptor antagonists on a rat model of neuroleptic-induced akathisia. ( Sachdev, PS; Saharov, T, 1997)
"We report on a patient with schizoaffective disorder who developed unilateral akathisia."	1.30	A case of neuroleptic-induced unilateral akathisia with periodic limb movements in the opposite side during sleep. ( Horiguchi, J; Inami, Y; Kuramoto, Y; Mizuno, S; Yamashita, H; Yamawaki, S, 1999)
" The aim of this study was to investigate possible pharmacokinetic interactions of neuroleptic haloperidol with the beta-blocker carteolol and the anticholinergic biperiden."	1.30	Pharmacokinetic and pharmacodynamic interactions among haloperidol, carteolol hydrochloride and biperiden hydrochloride. ( Aoki, S; Hisazumi, H; Isawa, S; Kudo, S; Kumagai, Y; Miura, S; Murasaki, M; Uchiumi, M; Yoshioka, M, 1999)
"Of 51 consecutive referrals to a Tourette's disorder clinic, 48 met DSM-III-R criteria for Tourette's disorder."	1.29	Causes of haloperidol discontinuation in patients with Tourette's disorder: management and alternatives. ( Barickman, J; Daniel, W; Friedhoff, AJ; Muñoz, DM; Silva, RR, 1996)
"The haloperidol-treated group showed a significant increase in the predrug bolus counts from week 5, suggesting a conditioned response to the cage environment."	1.29	Effect of prolonged treatment with haloperidol on "emotional" defecation and movement in rats in a well-habituated environment. ( Loneragan, C; Sachdev, P; Westbrook, F, 1994)
" Other adverse events interfering with the patients' social roles also interfere with the patients' willingness to comply with treatment."	1.29	Compliance with antipsychotic drug treatment: influence of side effects. ( Fleischhacker, WW; Günther, V; Kurz, M; Meise, U, 1994)
"The mean plasma cortisol level of the akathisia group was tended to be lower than that of the non-akathisia group."	1.27	[Biochemical and psychophysiological study of haloperidol-induced akathisia]. ( Odo, S, 1983)
"Four patients with akathisia as a result of neuroleptic administration were treated with amantadine."	1.27	Development of tolerance to the therapeutic effect of amantadine on akathisia. ( Barreira, P; Lipinski, JF; Zubenko, GS, 1984)
"Akathisia is a common but frequently unrecognized complication of antipsychotic medication."	1.27	Akathisia: the syndrome of motor restlessness. ( Friedman, JH; Wagner, RL, 1987)
"A patient with neuroleptic-induced akathisia was successfully treated with a combination of baclofen (a GABA agonist) and clonazepam (a serotonergic agent)."	1.27	Successful treatment of neuroleptic-induced akathisia with baclofen and clonazepam. A case report. ( Sandyk, R, 1985)
"Akathisia is an easily treatable but often overlooked extrapyramidal symptom induced by neuroleptic drugs."	1.26	Akathisia: an overlooked, distressing, but treatable condition. ( Shen, WW, 1981)

Research

Studies (102)

Authors

Clinical Trials (10)

Trial Overview

Trial Outcomes

Adherence Attitude Score as Measured by the Attitude Toward Medication Questionnaire (AMQ) at 12 Months

Timeframe	Studies, this research(%)	All Research%
pre-1990	22 (21.57)	18.7374
1990's	33 (32.35)	18.2507
2000's	23 (22.55)	29.6817
2010's	23 (22.55)	24.3611
2020's	1 (0.98)	2.80

Authors	Studies
Nagaoka, K	2
Nagayasu, K	2
Shirakawa, H	2
Kaneko, S	2
Juncal-Ruiz, M	1
Ramirez-Bonilla, M	1
Gomez-Arnau, J	1
Ortiz-Garcia de la Foz, V	1
Suarez-Pinilla, P	1
Martinez-Garcia, O	1
Neergaard, KD	1
Tabares-Seisdedos, R	1
Crespo-Facorro, B	1
Suzuki, K	1
Harada, A	1
Suzuki, H	1
Capuani, C	1
Ugolini, A	1
Corsi, M	1
Kimura, H	1
Hardman, MI	1
Sprung, J	1
Weingarten, TN	1
Bleickardt, CJ	1
Kazdoba, TM	1
Jones, NT	1
Hunter, JC	1
Hodgson, RA	1
Adams, CE	1
Bergman, H	1
Irving, CB	1
Lawrie, S	1
Sajatovic, M	1
Levin, J	1
Ramirez, LF	1
Hahn, DY	1
Tatsuoka, C	1
Bialko, CS	1
Cassidy, KA	1
Fuentes-Casiano, E	1
Williams, TD	1
McEvoy, JP	1
Byerly, M	1
Hamer, RM	1
Dominik, R	1
Swartz, MS	1
Rosenheck, RA	1
Ray, N	1
Lamberti, JS	1
Buckley, PF	1
Wilkins, TM	1
Stroup, TS	1
Hagino, Y	1
Kasai, S	1
Fujita, M	1
Setogawa, S	1
Yamaura, H	1
Yanagihara, D	1
Hashimoto, M	1
Kobayashi, K	1
Meltzer, HY	1
Ikeda, K	1
Forcen, FE	1
Matsoukas, K	1
Alici, Y	1
Widschwendter, CG	1
Karayal, ON	1
Kolluri, S	1
Vanderburg, D	1
Kemmler, G	1
Fleischhacker, WW	3
Rasmussen, SA	1
Rosebush, PI	1
Mazurek, MF	1
Shen, X	1
Purser, C	1
Tien, LT	1
Chiu, CT	1
Paul, IA	1
Baker, R	1
Loh, HH	1
Ho, IK	1
Ma, T	1
Correll, CU	1
Sheridan, EM	1
DelBello, MP	1
Desai, A	1
Nierenberg, DW	1
Duhaime, AC	1
Kane, JM	2
Cohen, M	1
Zhao, J	1
Alphs, L	1
Panagides, J	1
Pathan, AA	1
Mohan, M	1
Kasture, AS	1
Kasture, SB	1
Onishi, H	1
Wada, M	2
Wada, T	1
Ishida, M	1
Kawanishi, C	1
Mizuno, K	1
Ito, H	1
Narabayashi, M	1
Sasaki, Y	1
Kashyap, GL	1
Patel, AG	1
Fang, M	1
Chen, H	1
Li, LH	1
Wu, R	1
Li, Y	1
Liu, L	1
Ye, M	1
Huang, J	1
Zhu, S	1
Wang, G	1
Zhang, Q	1
Zheng, H	1
Zhang, L	1
Wang, B	1
Zhou, J	1
Zhao, JP	1
Kinon, BJ	1
Kollack-Walker, S	1
Stauffer, V	1
Liu-Seifert, H	1
Seemüller, F	2
Lewitzka, U	2
Bauer, M	1
Meyer, S	1
Musil, R	2
Schennach, R	2
Riedel, M	2
Doucette, S	1
Möller, HJ	3
Citrome, L	2
Mayr, A	1
Jäger, M	1
Maier, W	1
Klingenberg, S	1
Heuser, I	1
Klosterkötter, J	1
Gastpar, M	2
Schmitt, A	1
Schlösser, R	1
Schneider, F	1
Ohmann, C	1
Gaebel, W	1
Torner, C	1
Herrera-Estrella, M	1
Gutiérrez, JA	1
Aguilar-Roblero, R	1
Rosenheck, R	1
Perlick, D	1
Bingham, S	1
Liu-Mares, W	1
Collins, J	1
Warren, S	1
Leslie, D	1
Allan, E	1
Campbell, EC	1
Caroff, S	1
Corwin, J	1
Davis, L	1
Douyon, R	1
Dunn, L	1
Evans, D	1
Frecska, E	1
Grabowski, J	1
Graeber, D	1
Herz, L	1
Kwon, K	1
Lawson, W	1
Mena, F	1
Sheikh, J	1
Smelson, D	1
Smith-Gamble, V	1
Volavka, J	1
Glazer, WM	1
de Haan, L	1
van Beveren, N	1
Honer, WG	1
Kopala, LC	1
Rabinowitz, J	1
Kaye, NS	1
Park, JY	1
Shon, JH	1
Kim, KA	1
Jung, HJ	1
Shim, JC	1
Yoon, YR	1
Cha, IJ	1
Shin, JG	1
Yamauchi, K	1
Ohmori, T	1
Nasrallah, HA	1
Brecher, M	1
Paulsson, B	1
Bishnoi, M	2
Chopra, K	2
Kulkarni, SK	2
Sivrioglu, EY	1
Kirli, S	1
Sipahioglu, D	1
Gursoy, B	1
Sarandöl, E	1
Kim, JH	1
Byun, HJ	1
Burkhardt, JM	1
Constantinidis, C	1
Anstrom, KK	1
Roberts, DC	1
Woodward, DJ	1
Back, I	1
Taubert, M	1
Fink, M	1
Irwin, P	1
Zubenko, GS	1
Barreira, P	1
Lipinski, JF	1
Van Putten, T	2
May, PR	2
Marder, SR	2
Odo, S	1
Abraham, TM	1
Bruun, RD	2
Denijs, EL	1
Shen, WW	1
Owens, DG	1
Kurz, M	2
Hummer, M	1
Oberbauer, H	1
Sachdev, P	1
Loneragan, C	1
Westbrook, F	1
D'Souza, DC	1
Bennett, A	1
Abi-Dargham, A	1
Krystal, JH	1
Meise, U	1
Günther, V	1
Newcomer, JW	1
Miller, LS	1
Faustman, WO	1
Wetzel, MW	1
Vogler, GP	1
Csernansky, JG	1
Lang, AE	1
Tesar, GE	1
Mani, J	1
Tandel, SV	1
Shah, PU	1
Karnad, DR	1
Silva, RR	1
Muñoz, DM	1
Daniel, W	1
Barickman, J	1
Friedhoff, AJ	1
Anderson, BG	1
Reker, D	1
Cooper, T	1
Beasley, CM	2
Tollefson, G	1
Tran, P	1
Satterlee, W	1
Sanger, T	1
Hamilton, S	1
King, DJ	2
Burke, M	1
Lucas, RA	1
Lynch, G	1
Green, JF	1
Erdmann, R	1
Galynker, II	1
Nazarian, D	1
Kasper, S	1
Barnas, C	1
Heiden, A	1
Volz, HP	1
Laakmann, G	1
Zeit, H	1
Pfolz, H	1
Zimbroff, DL	1
Tamminga, CA	2
Daniel, DG	1
Mack, RJ	1
Wozniak, PJ	1
Sebree, TB	1
Wallin, BA	1
Kashkin, KB	1
Khan, LC	1
Lustik, SJ	1
Tollefson, GD	1
Tran, PV	1
Nemeroff, CB	1
Casey, DE	1
Boyer, P	1
Fleurot, O	1
Rein, W	1
Sachdev, PS	1
Saharov, T	1
Poyurovsky, M	2
Fuchs, C	1
Weizman, A	2
Conley, RR	1
Bartko, JJ	1
Richardson, C	1
Peszke, M	1
Lingle, J	1
Hegerty, J	1
Love, R	1
Gounaris, C	1
Zaremba, S	1
Breier, A	1
Hamilton, SH	1
Yamashita, H	1
Horiguchi, J	1
Mizuno, S	1
Kuramoto, Y	1
Yamawaki, S	1
Inami, Y	1
Isawa, S	1
Murasaki, M	1
Miura, S	2
Yoshioka, M	1
Uchiumi, M	1
Kumagai, Y	1
Aoki, S	1
Hisazumi, H	1
Kudo, S	1
Hermesh, H	1
Manor, I	1
Munitz, H	2
Gruber, O	1
Northoff, G	1
Pflug, B	1
Eichhammer, P	1
Albus, M	1
Borrmann-Hassenbach, M	1
Schoeler, A	1
Putzhammer, A	1
Frick, U	1
Klein, HE	1
Rohrmeier, T	1
Havaki-Kontaxaki, BJ	1
Kontaxakis, VP	1
Christodoulou, GN	1
Hirose, S	1
Ashby, CR	1
Fehr, C	1
Dahmen, N	1
Klawe, C	1
Eicke, M	1
Szegedi, A	1
Ishigooka, J	1
Inada, T	1
Holzbach, E	1
Bühler, KE	1
Caine, ED	1
Polinsky, RJ	1
Keckich, WA	1
Nordström, AL	1
Farde, L	1
Halldin, C	1
Cookson, JC	1
Kastrup, O	1
Eikmeier, G	1
Shaw, ED	1
Mann, JJ	1
Weiden, PJ	1
Sinsheimer, LM	1
Brunn, RD	1
Shalev, A	1
Friedman, JH	1
Wagner, RL	1
Herrera, JN	1
Sramek, JJ	1
Costa, JF	1
Roy, S	1
Heh, CW	1
Nguyen, BN	1
Stein, MB	1
Pohlman, ER	1
Claghorn, JL	1
Schibuk, M	1
Schachter, D	1
Drake, RE	1
Ehrlich, J	1
Sandyk, R	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Prospective Trial of Customized Adherence Enhancement Plus Long-acting Injectable Antipsychotic (CAE-L) in Individuals With Schizophrenia or Schizoaffective Disorder at Risk for Treatment Non-adherence and for Homelessness[NCT01152697]		30 participants (Actual)	Interventional	2010-06-30	Completed
A Comparison of Long-Acting Injectable Medications for Schizophrenia[NCT01136772]	Phase 4	311 participants (Actual)	Interventional	2011-03-31	Completed
Comparative Efficacy and Acceptability of Lithium, Valproate, Oxcarbazepine, Quetiapine, Olanzapine, and Ziprasidone in Bipolar I Disorder, Manic or Mixed Phase[NCT01893229]	Phase 4	120 participants (Anticipated)	Interventional	2013-09-30	Recruiting
A Multicenter, Randomized, Double-Blind, Fixed-Dose, 6-Week Trial of the Efficacy and Safety of Asenapine Compared With Placebo Using Haloperidol Positive Control in Subjects With an Acute Exacerbation of Schizophrenia[NCT00156104]	Phase 3	460 participants (Actual)	Interventional	2005-07-01	Completed
Maintenance Treatment vs. Stepwise Drug Discontinuation After One Year of Maintenance Treatment in First-Episode Schizophrenia[NCT00159120]	Phase 4	71 participants (Anticipated)	Interventional	2001-11-30	Completed
CSP #451 - The Clinical and Economic Impact of Olanzapine in the Treatment of Schizophrenia[NCT00007774]	Phase 4	600 participants (Anticipated)	Interventional	1998-03-31	Completed
a Pilot Study of Pramipexole to Treat Extrapyramidal Symptoms Induced by Antipsychotics[NCT03430596]	Early Phase 1	50 participants (Actual)	Interventional	2018-05-01	Completed
A Placebo-Controlled, Cross-Over Trial of Aripiprazole Added to Obese Olanzapine-Treated Patients With Schizophrenia[NCT00351936]	Phase 4	16 participants (Actual)	Interventional	2005-12-31	Completed
Study of the Vascular Response to Percutaneous Coronary Intervention in Patients With Non-ST-elevation Acute Coronary Syndromes Using Intravascular Blood Sampling[NCT03300167]		0 participants (Actual)	Interventional	2017-11-30	Withdrawn (stopped due to Delivery of equipment. PI not had any further interaction with the company so closed study.)
Behavior Therapy and Psychosocial Treatment for Tourette Syndrome and Chronic Tic Disorder[NCT00231985]	Phase 2	122 participants (Actual)	Interventional	2005-10-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Nineteen item inventory taken by the participant with Scale Range:0-19. Lower scores indicate improved outcomes. (NCT01152697)
Timeframe: 12 months

Adherence Attitude Score as Measured by the Drug Attitude Inventory (DAI) at 12 Months

Intervention	units on a scale (Mean)
Patient Noncompliance	2.43

Ten item inventory taken by the participant with a Scale Range: 0-10. Higher scores indicate improved outcomes. (NCT01152697)
Timeframe: 12 months

Days Homeless Out of the Previous 6 Months as Measured at 12 Months

Intervention	units on a scale (Mean)
Patient Noncompliance	7.00

Subjects will be asked how many days they have been homeless (NCT01152697)
Timeframe: 12 months

Frequency of Health Resource Use in the Past 3 Months as Measured at 25 Weeks

Intervention	days (Mean)
Patient Noncompliance	35

The frequency of health resource use will be measured through interview of the participant. (NCT01152697)
Timeframe: 25 weeks

Treatment Adherence Behavior Score as Measured by the Morisky Medication Rating Scale at 12 Months

Intervention	days (Mean)
Patient Noncompliance	20.18

Four item inventory taken by participant with Scale Range: 0-4. Lower scores indicate better outcomes. (NCT01152697)
Timeframe: 12 months

Treatment Satisfaction as Measured by the Participant Acceptability and Satisfaction Questionnaire at 12 Months

Intervention	units on a scale (Mean)
Patient Noncompliance	1.33

"Satisfaction will be measured by a seven item inventory taken by the participant.~Scale ranges from 1 (Strongly Agree) to 5 (Strongly Disagree). Lower scores indicate better outcomes, while higher scores indicate worse outcomes. The highest possible score is 35." (NCT01152697)
Timeframe: 12 months

Treatment Satisfaction as Measured by the Participant Acceptability and Satisfaction Questionnaire at 25 Weeks

Intervention	units on a scale (Mean)
Patient Noncompliance	12.33

Change From Baseline in Adherence Attitude Score as Measured by the Attitude Toward Medication Questionnaire (AMQ) at 25 Weeks

Intervention	units on a scale (Mean)
Patient Noncompliance	12.12

Nineteen item inventory taken by the participant with Scale Range:0-19. Lower scores indicate improved outcomes. (NCT01152697)
Timeframe: Baseline-25 weeks

Change From Baseline in Adherence Attitude Score as Measured by the Drug Attitude Inventory (DAI) at 25 Weeks

Intervention	units on a scale (Mean)
	Baseline	Week 25
Patient Noncompliance	6.63	4.47

Ten item inventory taken by the participant with a Scale Range: 0-10. Higher scores indicate improved outcomes. (NCT01152697)
Timeframe: Baseline-25 weeks

Change From Baseline in Days Homeless Out of the Previous 6 Months as Measured at 25 Weeks

Intervention	units on a scale (Mean)
	Baseline	Week 25
Patient Noncompliance	7.47	8.07

Subjects will be asked how many days they have been homeless (NCT01152697)
Timeframe: Baseline-25 weeks

Change From Baseline in Treatment Adherence Behavior Score as Measured by the Morisky Medication Rating Scale at 25 Weeks

Intervention	days (Mean)
	Baseline	25 Weeks
Patient Noncompliance	6.50	9.85

Four item inventory taken by participant with Scale Range: 0-4. Lower scores indicate improved outcomes. (NCT01152697)
Timeframe: Baseline-25 weeks

Change From Baseline in Treatment Adherence Score as Measured at 25 Weeks

Intervention	units on a scale (Mean)
	Baseline	Week 25
Patient Noncompliance	2.31	1.19

A total treatment adherence score will calculated as a proportion of medications taken as reported from the participant, and evidenced by pill counts and documented medication injections. (NCT01152697)
Timeframe: Baseline-25 weeks

Change in Global Psychopathology as Measured by the Clinical Global Impressions (CGI) at 25 Weeks

Intervention	Percentage of doses (Mean)
	Past week	Past month
Patient Noncompliance	30.91	10.10

"Global psychopathology will be measured with the Clinical Global Impressions (CGI) (Guy 1976) a widely used scale which evaluates illness severity on a 1 to 7 point continuum. Severity of illness ratings on the CGI have reported reliability scores ranging from 0.41-0.66 (Guy 1976) Lower scores indicate improved outcomes. Higher scores indicate worse outcomes.~Illness scale: 1 - 7 (1 = Normal/not at all ill ; 7 = Among the most extremely ill patients) Global improvement scale: 1 - 7 (1 = Very much improved ; 7 = Very much worse)" (NCT01152697)
Timeframe: Baseline-25 weeks

Change in Schizophrenia and Schizoaffective Disorder Symptom Severity Scale as Measured by the Positive and Negative Syndrome Scale (PANSS) at 25 Weeks

Intervention	units on a scale (Mean)
	Baseline - Severity	Week 25 - Severity	Baseline - Global Improvement	Week 25 - Global Improvement
Patient Noncompliance	4.76	3.24	3.43	2.14

"The PANSS (Kay, Fiszbein, & Opler 1987) was created to assess both the positive and negative symptoms of schizophrenia such as hallucinations and emotional withdrawal, respectively. The scale rates 30 symptoms on a scale from 1 (absent) to 7 (extreme) and has been shown to limit bias between the assessment of positive and negative symptoms, providing a broad but balanced spectrum of the illness.~There are three subscales: positive symptoms, negative symptoms, general psychopathology. Potential responses to Items on all subscales range from 1 (absent) to 7 (extreme). Lower scores indicate lower symptoms and, therefore, better outcomes. Higher scores indicate more presence of symptoms and, therefore, worse outcomes.~Subscales are combined to produce a total score, which is summed from all of the subscales. Lower total scores indicate lower symptoms and, therefore, better outcomes. Higher total scores indicate more presence of symptoms and, therefore, worse outcomes." (NCT01152697)
Timeframe: Baseline-25 weeks

Change in Serious Mental Illness Severity Score as Measured by the Brief Psychiatric Rating Scale (BPRS) at 25 Weeks

Intervention	units on a scale (Mean)
	Baseline	Week 25
Patient Noncompliance	46.37	32.84

"The BPRS, developed by Overall and Gorham (1962), is a widely used, relatively brief scale that measures major psychotic and non-psychotic symptoms in individuals with SMI. The 18-item BPRS is well-validated and is perhaps the most researched instrument in psychiatry. Reliability coefficients are reported to be in the range of 0.56-0.87.~Scale Range: 18-126 Lower scores represent improved outcomes." (NCT01152697)
Timeframe: Baseline-25 weeks

Change in Social and Occupational Functioning Scale (SOFAS) as Measured at 12 Months

Intervention	units on a scale (Mean)
	Baseline	Week 25
Patient Noncompliance	46.37	32.84

Life and Work Functional status will be evaluated using the Social and Occupational Functioning Scale (SOFAS), which is derived from the GAF. The GAF is a 100-point single-item scale which measures global functioning of psychiatric patients and is widely utilized in clinical studies involving Seriously Mentally Ill patients (Jones 1995). The reliability of the GAF ranges from 0.62-0.82. Higher scores indicate improved outcomes. (NCT01152697)
Timeframe: Baseline-12 months

Change in Social and Occupational Functioning Scale (SOFAS) as Measured at 25 Weeks

Intervention	units on a scale (Mean)
	Baseline	12 months
Patient Noncompliance	45.33	63.83

Life and Work Functional status will be evaluated using the Social and Occupational Functioning Scale (SOFAS), which is derived from the GAF (Global Assessment of Functioning). The GAF is a 100-point single-item scale which measures global functioning of psychiatric patients and is widely utilized in clinical studies involving Seriously Mentally Ill patients (Jones 1995). The reliability of the GAF ranges from 0.62-0.82. Higher scores indicate improved outcomes. (NCT01152697)
Timeframe: Baseline-25 weeks

Frequency of Health Resource Use Throughout Months 10, 11, and 12

Intervention	units on a scale (Mean)
	Baseline	Week 25
Patient Noncompliance	47.35	58.65

The frequency of health resource use will be measured through interview of the participant. (NCT01152697)
Timeframe: Month 1-3, Month 10-12

Global Psychopathology as Measured by the Clinical Global Impressions (CGI) at 12 Months

Intervention	days (Mean)
	3 Month	12 Month
Patient Noncompliance	19.33	15.50

Treatment Adherence Score as Measured at 12 Months

Intervention	units on a scale (Mean)
	Severity	Global Improvement
Patient Noncompliance	3.17	2.42

Changes in Psychiatric Symptoms

Intervention	Percentage of doses (Mean)
	Past Week	Past Month
Patient Noncompliance	28.65	6

The Positive and Negative Syndrome Scale measures the core symptoms associated with schizophrenia. The measure includes 30 items rated from 1=absent to 7=extremely severe. Full range of scores is 30-210 with higher scores representing more severe illness. Reductions in symptoms over time represent improvement. (NCT01136772)
Timeframe: Baseline to 6 months

Efficacy Failure

Intervention	Units on a scale (Mean)
Paliperidone Palmitate	-6.87
Haloperidol Decanoate	-6.40

Efficacy failure as indicated by psychiatric hospitalization, need for crisis intervention, clinical decision that oral antipsychotic medication cannot be discontinued in less than eight weeks, a clinical decision to discontinue the medication due to inadequate benefit, or the ongoing or repeated need for adjunctive antipsychotic medication. (NCT01136772)
Timeframe: 24 months

Change From Baseline in Body Mass Index (BMI)

Intervention	participants (Number)
Paliperidone Palmitate	49
Haloperidol Decanoate	47

Evaluating change in Body Mass Index (BMI) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4

Change From Baseline in Fasting Total Cholesterol

Intervention	kg/m^2 (Mean)
Aripiprazole	-0.4
Placebo	0.3

Evaluating change in fasting total cholesterol between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4

Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C)

Intervention	mg/dL (Mean)
Aripiprazole	-3
Placebo	9

Evaluating change in high-density lipoprotein cholesterol (HDL-C) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4

Change From Baseline in Low-density Lipoprotein (LDL)

Intervention	mg/dL (Mean)
Aripiprazole	0.4
Placebo	0.6

Evaluating change in low-density lipoprotein (LDL) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4

Change From Baseline in Triglycerides

Intervention	mg/dL (Mean)
Aripiprazole	-0.2
Placebo	3.1

Evaluating change in triglyceride levels between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4

Change From Baseline in Waist-hip Ratio (WHR)

Intervention	mg/dL (Mean)
Aripiprazole	-51.7
Placebo	47.6

Evaluating change in waist-hip ratio (WHR) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4

Change From Baseline in Weight (Lbs)

Intervention	cm (Mean)
Aripiprazole	0.0
Placebo	0.0

Evaluating change in weight (lbs) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4

Article	Year
Acute phenibut withdrawal: A comprehensive literature review and illustrative case report. Bosnian journal of basic medical sciences, 2019, May-20, Volume: 19, Issue:2 Topics: Akathisia, Drug-Induced; Baclofen; Cyproheptadine; Dexmedetomidine; Diphenhydramine; GABA-A Receptor	2019
Haloperidol versus placebo for schizophrenia. The Cochrane database of systematic reviews, 2013, Nov-15, Issue:11 Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Dystonia; Haloperidol; Humans; Parkinsonian Disorders	2013
Antipsychotic-induced akathisia in delirium: A systematic review. Palliative & supportive care, 2016, Volume: 14, Issue:1 Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Delirium; Haloperidol; Humans; Prevalence; Risperidon	2016
Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials. Bipolar disorders, 2010, Volume: 12, Issue:2 Topics: Adolescent; Adult; Age Factors; Akathisia, Drug-Induced; Anti-Obesity Agents; Antimanic Agents; Anti	2010
[Two cases of tardive Tourette syndrome]. Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica, 2006, Volume: 108, Issue:5 Topics: Adult; Akathisia, Drug-Induced; Alcoholism; Amantadine; Antipsychotic Agents; Cholinergic Antagonist	2006
Extrapyramidal side effects and tolerability of risperidone: a review. The Journal of clinical psychiatry, 1994, Volume: 55 Suppl Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Clinical Trials as Topic; Dyskinesia, Drug-Induced; D	1994
Withdrawal akathisia: case reports and a proposed classification of chronic akathisia. Movement disorders : official journal of the Movement Disorder Society, 1994, Volume: 9, Issue:2 Topics: Adolescent; Adult; Akathisia, Drug-Induced; Bipolar Disorder; Dose-Response Relationship, Drug; Drug	1994
The agitated patient, Part II: Pharmacologic treatment. Hospital & community psychiatry, 1993, Volume: 44, Issue:7 Topics: Akathisia, Drug-Induced; Drug Therapy, Combination; Emergencies; Haloperidol; Humans; Lorazepam; Neu	1993
[Nicotine in neuropsychiatric movement disorders]. Fortschritte der Neurologie-Psychiatrie, 1996, Volume: 64, Issue:9 Topics: Adult; Akathisia, Drug-Induced; Brain; Child; Dyskinesia, Drug-Induced; Haloperidol; Humans; Nicotin	1996
Safety of olanzapine. The Journal of clinical psychiatry, 1997, Volume: 58 Suppl 10 Topics: Acute Disease; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Blood Pressure; Clini	1997
Dosing the antipsychotic medication olanzapine. The Journal of clinical psychiatry, 1997, Volume: 58 Suppl 10 Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Dose-Respons	1997
The relationship of pharmacology to side effects. The Journal of clinical psychiatry, 1997, Volume: 58 Suppl 10 Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; D	1997
The neuroleptic malignant syndrome: agent and host interaction. Acta psychiatrica Scandinavica, 1986, Volume: 73, Issue:4 Topics: Adolescent; Adult; Aftercare; Aged; Akathisia, Drug-Induced; Amantadine; Antiparkinson Agents; Antip	1986

Article	Year
Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment. Psychopharmacology, 2017, Volume: 234, Issue:17 Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Female; Haloper	2017
Prospective trial of customized adherence enhancement plus long-acting injectable antipsychotic medication in homeless or recently homeless individuals with schizophrenia or schizoaffective disorder. The Journal of clinical psychiatry, 2013, Volume: 74, Issue:12 Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Delayed-Action Preparations; Female; Haloperid	2013
Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. JAMA, 2014, May-21, Volume: 311, Issue:19 Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Double-Blind Method; Female; Haloperidol; Hosp	2014
Relating Spontaneously Reported Extrapyramidal Adverse Events to Movement Disorder Rating Scales. The international journal of neuropsychopharmacology, 2015, Jun-26, Volume: 18, Issue:12 Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Double-Blind Method; Haloper	2015
Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. Journal of clinical psychopharmacology, 2010, Volume: 30, Issue:2 Topics: Acute Disease; Adult; Akathisia, Drug-Induced; Dibenzocycloheptenes; Double-Blind Method; Female; Ha	2010
Comparison of risperidone oral solution and intramuscular haloperidol with the latter shifting to oral therapy for the treatment of acute agitation in patients with schizophrenia. International clinical psychopharmacology, 2012, Volume: 27, Issue:2 Topics: Administration, Oral; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; China; Clonazepam; Diagn	2012
The relationship of Akathisia with treatment emergent suicidality among patients with first-episode schizophrenia treated with haloperidol or risperidone. Pharmacopsychiatry, 2012, Volume: 45, Issue:7 Topics: Adolescent; Adult; Age Factors; Akathisia, Drug-Induced; Antipsychotic Agents; Anxiety; Female; Halo	2012
Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed? Clinical schizophrenia & related psychoses, 2012, Volume: 6, Issue:2 Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Cholesterol; D	2012
Akathisia and suicidal ideation in first-episode schizophrenia. Journal of clinical psychopharmacology, 2012, Volume: 32, Issue:5 Topics: Adult; Age Factors; Akathisia, Drug-Induced; Antipsychotic Agents; Depression; Double-Blind Method;	2012
Diurnal variations of extrapyramidal symptoms induced by haloperidol in schizophrenic subjects. The international journal of neuropsychopharmacology, 2003, Volume: 6, Issue:3 Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Circadian Rhythm; Cros	2003
Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA, 2003, Nov-26, Volume: 290, Issue:20 Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Benztropine; Double-Blind Met	2003
Extrapyramidal symptoms and signs in first-episode, antipsychotic exposed and non-exposed patients with schizophrenia or related psychotic illness. Journal of psychopharmacology (Oxford, England), 2005, Volume: 19, Issue:3 Topics: Adolescent; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Double-Bli	2005
Combined effects of itraconazole and CYP2D610 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects. Journal of clinical psychopharmacology, 2006, Volume: 26, Issue:2* Topics: Adult; Akathisia, Drug-Induced; Antifungal Agents; Antipsychotic Agents; Cytochrome P-450 CYP2D6; Cy	2006
The impact of omega-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: an open-label pilot study. Progress in neuro-psychopharmacology & biological psychiatry, 2007, Oct-01, Volume: 31, Issue:7 Topics: Adolescent; Adult; Akathisia, Drug-Induced; Antioxidants; Antipsychotic Agents; Ascorbic Acid; Eryth	2007
EEG and behavioral profile of flutroline (CP-36,584), a novel antipsychotic drug. Psychopharmacology, 1980, Volume: 72, Issue:1 Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Behavior; Carbolines; Clinical Trials as Topic	1980
Akathisia with haloperidol and thiothixene. Archives of general psychiatry, 1984, Volume: 41, Issue:11 Topics: Adult; Akathisia, Drug-Induced; Anxiety Disorders; Depressive Disorder; Dose-Response Relationship,	1984
Clinical evaluation of bromperidol versus haloperidol in psychotic patients. International pharmacopsychiatry, 1980, Volume: 15, Issue:5 Topics: Adult; Aged; Akathisia, Drug-Induced; Clinical Trials as Topic; Double-Blind Method; Drug Tolerance;	1980
Extrapyramidal side effects of clozapine and haloperidol. Psychopharmacology, 1995, Volume: 118, Issue:1 Topics: Adult; Akathisia, Drug-Induced; Basal Ganglia Diseases; Clozapine; Dyskinesia, Drug-Induced; Female;	1995
Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 1996, Volume: 14, Issue:2 Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Dose-Respon	1996
Antipsychotic drug-induced dysphoria. The British journal of psychiatry : the journal of mental science, 1996, Volume: 169, Issue:4 Topics: Adolescent; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Depression; Double-Blind Method; H	1996
Pramipexole as adjunct to haloperidol in schizophrenia. Safety and efficacy. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 1997, Volume: 7, Issue:1 Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Benzothiazoles; Dopamine Agonists; Drug Therap	1997
Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. The American journal of psychiatry, 1997, Volume: 154, Issue:6 Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Chro	1997
Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group. Psychopharmacology, 1997, Volume: 132, Issue:4 Topics: Adult; Akathisia, Drug-Induced; Amisulpride; Antipsychotic Agents; Brief Psychiatric Rating Scale; D	1997
Low-dose mianserin in treatment of acute neuroleptic-induced akathisia. Journal of clinical psychopharmacology, 1998, Volume: 18, Issue:3 Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Female; Haloperidol; Humans; Male; Mianserin;	1998
Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. The American journal of psychiatry, 1998, Volume: 155, Issue:7 Topics: Adult; Akathisia, Drug-Induced; Analysis of Variance; Antipsychotic Agents; Basal Ganglia Diseases;	1998
Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia. Biological psychiatry, 1999, Feb-15, Volume: 45, Issue:4 Topics: Adult; Akathisia, Drug-Induced; Analysis of Variance; Antipsychotic Agents; Behavioral Symptoms; Ben	1999
Intravenous biperiden in akathisia: an open pilot study. International journal of psychiatry in medicine, 2000, Volume: 30, Issue:2 Topics: Acute Disease; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Biperiden; Cholinergic Antagoni	2000
Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: results of the Japan multicenter, double-blind olanzapine trial. Psychiatry and clinical neurosciences, 2001, Volume: 55, Issue:4 Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Double-Blind	2001
Side effects during long-term treatment with depot antipsychotic medication. Clinical neuropharmacology, 1991, Volume: 14 Suppl 2 Topics: Akathisia, Drug-Induced; Delayed-Action Preparations; Double-Blind Method; Dyskinesia, Drug-Induced;	1991
A case of suicidal and homicidal ideation and akathisia in a double-blind neuroleptic crossover study. Journal of clinical psychopharmacology, 1986, Volume: 6, Issue:3 Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Carbazoles; Clinical Trials as Topic; Double-B	1986
High potency neuroleptics and violence in schizophrenics. The Journal of nervous and mental disease, 1988, Volume: 176, Issue:9 Topics: Adult; Akathisia, Drug-Induced; Chlorpromazine; Clozapine; Haloperidol; Humans; Schizophrenia; Schiz	1988
Review of clinical and laboratory experiences with molindone hydrochloride. The Journal of clinical psychiatry, 1985, Volume: 46, Issue:8 Pt 2 Topics: Akathisia, Drug-Induced; Basal Ganglia Diseases; Clinical Trials as Topic; Dose-Response Relationshi	1985

Article	Year
Acetaminophen improves tardive akathisia induced by dopamine D Journal of pharmacological sciences, 2023, Volume: 151, Issue:1 Topics: Acetaminophen; Akathisia, Drug-Induced; Animals; Antipsychotic Agents; Dopamine; Dopamine D2 Recepto	2023
Acetaminophen improves tardive akathisia induced by dopamine D Journal of pharmacological sciences, 2023, Volume: 151, Issue:1 Topics: Acetaminophen; Akathisia, Drug-Induced; Animals; Antipsychotic Agents; Dopamine; Dopamine D2 Recepto	2023
Acetaminophen improves tardive akathisia induced by dopamine D Journal of pharmacological sciences, 2023, Volume: 151, Issue:1 Topics: Acetaminophen; Akathisia, Drug-Induced; Animals; Antipsychotic Agents; Dopamine; Dopamine D2 Recepto	2023
Acetaminophen improves tardive akathisia induced by dopamine D Journal of pharmacological sciences, 2023, Volume: 151, Issue:1 Topics: Acetaminophen; Akathisia, Drug-Induced; Animals; Antipsychotic Agents; Dopamine; Dopamine D2 Recepto	2023
Combined treatment with a selective PDE10A inhibitor TAK-063 and either haloperidol or olanzapine at subeffective doses produces potent antipsychotic-like effects without affecting plasma prolactin levels and cataleptic responses in rodents. Pharmacology research & perspectives, 2018, Volume: 6, Issue:1 Topics: Administration, Oral; Akathisia, Drug-Induced; Animals; Antipsychotic Agents; Benzodiazepines; Catal	2018
Antagonism of the adenosine A2A receptor attenuates akathisia-like behavior induced with MP-10 or aripiprazole in a novel non-human primate model. Pharmacology, biochemistry, and behavior, 2014, Volume: 118 Topics: Adenosine A2 Receptor Antagonists; Akathisia, Drug-Induced; Animals; Antipsychotic Agents; Aripipraz	2014
Involvement of cholinergic system in hyperactivity in dopamine-deficient mice. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2015, Mar-13, Volume: 40, Issue:5 Topics: Acetylcholine; Akathisia, Drug-Induced; Animals; Anti-Dyskinesia Agents; Antipsychotic Agents; Centr	2015
The Relationship Between Early Haloperidol Response and Associated Extrapyramidal Side Effects. Journal of clinical psychopharmacology, 2017, Volume: 37, Issue:1 Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Brief Psychiatric Rating Scale; Dyskinesia, Dr	2017
mu-Opioid receptor knockout mice are insensitive to methamphetamine-induced behavioral sensitization. Journal of neuroscience research, 2010, Aug-01, Volume: 88, Issue:10 Topics: Akathisia, Drug-Induced; Amphetamine; Animals; Central Nervous System Stimulants; Dopamine Antagonis	2010
Akathisia after mild traumatic head injury. Journal of neurosurgery. Pediatrics, 2010, Volume: 5, Issue:5 Topics: Accidental Falls; Adolescent; Akathisia, Drug-Induced; Antipsychotic Agents; Athletic Injuries; Bicy	2010
Mucuna pruriens attenuates haloperidol-induced orofacial dyskinesia in rats. Natural product research, 2011, Volume: 25, Issue:8 Topics: Akathisia, Drug-Induced; Animals; Antioxidants; Free Radicals; Haloperidol; Male; Mucuna; Plant Extr	2011
Diagnosis and treatment of akathisia in a cancer patient who cannot stand up or sit down, because of poor performance status: factors that make the diagnosis of akathisia difficult, and diagnosis clues. Palliative & supportive care, 2010, Volume: 8, Issue:4 Topics: Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Bed Rest; Depressive Disorder, Major; Diagnosis	2010
Unusual presentation of a patient with GBL withdrawal: a case report. Psychiatria Danubina, 2011, Volume: 23 Suppl 1 Topics: 4-Butyrolactone; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Chlorpromazine; Delirium; Hal	2011
Reduction in tardive dyskinesia symptoms during treatment with olanzapine or haloperidol. Journal of clinical psychopharmacology, 2012, Volume: 32, Issue:3 Topics: Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Ratin	2012
Olanzapine vs haloperidol for treatment of schizophrenia. JAMA, 2004, Mar-03, Volume: 291, Issue:9 Topics: Akathisia, Drug-Induced; Anti-Dyskinesia Agents; Antipsychotic Agents; Benzodiazepines; Benztropine;	2004
Olanzapine vs haloperidol for treatment of schizophrenia. JAMA, 2004, Mar-03, Volume: 291, Issue:9 Topics: Akathisia, Drug-Induced; Anti-Dyskinesia Agents; Antipsychotic Agents; Benzodiazepines; Benztropine;	2004
Olanzapine vs haloperidol for treatment of schizophrenia. JAMA, 2004, Mar-03, Volume: 291, Issue:9 Topics: Akathisia, Drug-Induced; Anti-Dyskinesia Agents; Antipsychotic Agents; Benzodiazepines; Benztropine;	2004
Infanticide. The American journal of psychiatry, 2005, Volume: 162, Issue:6 Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Depression, Postpartum; Expert Testimony; Female; For	2005
Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania. Bipolar disorders, 2006, Volume: 8, Issue:5 Pt 1 Topics: Adult; Akathisia, Drug-Induced; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Basal Gangl	2006
Involvement of adenosinergic receptor system in an animal model of tardive dyskinesia and associated behavioural, biochemical and neurochemical changes. European journal of pharmacology, 2006, Dec-15, Volume: 552, Issue:1-3 Topics: Adenosine; Akathisia, Drug-Induced; Animals; Antioxidants; Behavior, Animal; Brain; Caffeine; Catala	2006
Protective effect of rutin, a polyphenolic flavonoid against haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes. Fundamental & clinical pharmacology, 2007, Volume: 21, Issue:5 Topics: Akathisia, Drug-Induced; Animals; Antioxidants; Antipsychotic Agents; Behavior, Animal; Brain; Disea	2007
Association of subjective cognitive dysfunction with akathisia in patients receiving stable doses of risperidone or haloperidol. Journal of clinical pharmacy and therapeutics, 2007, Volume: 32, Issue:5 Topics: Adult; Akathisia, Drug-Induced; Analysis of Variance; Antipsychotic Agents; Cognition Disorders; Fem	2007
Synchronous oscillations and phase reorganization in the basal ganglia during akinesia induced by high-dose haloperidol. The European journal of neuroscience, 2007, Volume: 26, Issue:7 Topics: Action Potentials; Akathisia, Drug-Induced; Animals; Basal Ganglia; Dopamine Antagonists; Functional	2007
Akathisia and an unusual symptomatic treatment: a case report. Palliative medicine, 2007, Volume: 21, Issue:8 Topics: Akathisia, Drug-Induced; Cyclizine; Exercise Therapy; Female; Fluoxetine; Haloperidol; Humans; Metho	2007
Development of tolerance to the therapeutic effect of amantadine on akathisia. Journal of clinical psychopharmacology, 1984, Volume: 4, Issue:4 Topics: Adult; Akathisia, Drug-Induced; Amantadine; Bipolar Disorder; Drug Tolerance; Female; Haloperidol; H	1984
[Biochemical and psychophysiological study of haloperidol-induced akathisia]. Yakubutsu, seishin, kodo = Japanese journal of psychopharmacology, 1983, Volume: 3, Issue:1 Topics: Action Potentials; Adult; Akathisia, Drug-Induced; Autonomic Nervous System; Emotions; Haloperidol;	1983
Response to antipsychotic medication: the doctor's and the consumer's view. The American journal of psychiatry, 1984, Volume: 141, Issue:1 Topics: Adult; Akathisia, Drug-Induced; Attitude of Health Personnel; Attitude to Health; Basal Ganglia Dise	1984
Unusual presentation after an overdose of haloperidol. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 1984, Volume: 29, Issue:1 Topics: Adult; Akathisia, Drug-Induced; Hallucinations; Haloperidol; Humans; Male	1984
Dysphoric phenomena associated with haloperidol treatment of Tourette syndrome. Advances in neurology, 1982, Volume: 35 Topics: Adult; Akathisia, Drug-Induced; Child; Depression; Female; Haloperidol; Humans; Male; Tourette Syndr	1982
Akathisia: an overlooked, distressing, but treatable condition. The Journal of nervous and mental disease, 1981, Volume: 169, Issue:9 Topics: Akathisia, Drug-Induced; Antiparkinson Agents; Female; Haloperidol; Humans; Middle Aged; Psychomotor	1981
Effect of prolonged treatment with haloperidol on "emotional" defecation and movement in rats in a well-habituated environment. Psychiatry research, 1994, Volume: 54, Issue:1 Topics: Akathisia, Drug-Induced; Animals; Defecation; Emotions; Habituation, Psychophysiologic; Haloperidol;	1994
Precipitation of a psychoneuromotor syndrome by fluoxetine in a haloperidol-treated schizophrenic patient. Journal of clinical psychopharmacology, 1994, Volume: 14, Issue:5 Topics: Akathisia, Drug-Induced; Drug Therapy, Combination; Fluoxetine; Haloperidol; Humans; Male; Middle Ag	1994
Compliance with antipsychotic drug treatment: influence of side effects. Acta psychiatrica Scandinavica. Supplementum, 1994, Volume: 382 Topics: Adult; Age Factors; Akathisia, Drug-Induced; Antipsychotic Agents; Clozapine; Female; Haloperidol; H	1994
Correlations between akathisia and residual psychopathology: a by-product of neuroleptic-induced dysphoria. The British journal of psychiatry : the journal of mental science, 1994, Volume: 164, Issue:6 Topics: Adult; Aged; Akathisia, Drug-Induced; Anxiety Disorders; Depressive Disorder; Dose-Response Relation	1994
Prolonged neurological sequelae after combination treatment with lithium and antipsychotic drugs. Journal of neurology, neurosurgery, and psychiatry, 1996, Volume: 60, Issue:3 Topics: Adult; Akathisia, Drug-Induced; Anti-Dyskinesia Agents; Antidepressive Agents; Bipolar Disorder; Dia	1996
Causes of haloperidol discontinuation in patients with Tourette's disorder: management and alternatives. The Journal of clinical psychiatry, 1996, Volume: 57, Issue:3 Topics: Adolescent; Adult; Affect; Affective Symptoms; Age of Onset; Akathisia, Drug-Induced; Antipsychotic	1996
Drug-induced dysphoria. The British journal of psychiatry : the journal of mental science, 1996, Volume: 168, Issue:4 Topics: Administration, Oral; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Depressive Disorder; Fem	1996
Antipsychotic drug-induced dysphoria. The British journal of psychiatry : the journal of mental science, 1995, Volume: 167, Issue:4 Topics: Adult; Akathisia, Drug-Induced; Anti-Dyskinesia Agents; Antipsychotic Agents; Depressive Disorder; F	1995
Akathisia as violence. The Journal of clinical psychiatry, 1997, Volume: 58, Issue:1 Topics: Akathisia, Drug-Induced; Bipolar Disorder; Diagnosis, Differential; Haloperidol; Humans; Male; Middl	1997
Treatment of a paradoxical reaction to midazolam with haloperidol. Anesthesia and analgesia, 1997, Volume: 85, Issue:1 Topics: Akathisia, Drug-Induced; Anti-Anxiety Agents; Antipsychotic Agents; Haloperidol; Humans; Hypnotics a	1997
The effects of beta-adrenoceptor antagonists on a rat model of neuroleptic-induced akathisia. Psychiatry research, 1997, Sep-19, Volume: 72, Issue:2 Topics: Adrenergic beta-Antagonists; Akathisia, Drug-Induced; Animals; Antipsychotic Agents; Arousal; Catale	1997
A case of neuroleptic-induced unilateral akathisia with periodic limb movements in the opposite side during sleep. Psychiatry and clinical neurosciences, 1999, Volume: 53, Issue:2 Topics: Acute Disease; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Dominance, Cerebral; Dose-Respo	1999
Pharmacokinetic and pharmacodynamic interactions among haloperidol, carteolol hydrochloride and biperiden hydrochloride. Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology, 1999, Volume: 19, Issue:3 Topics: Adrenergic beta-Antagonists; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Biperiden; Carteo	1999
Propranolol: a treatment for pseudoakathisia. The Journal of nervous and mental disease, 1994, Volume: 182, Issue:4 Topics: Adult; Agnosia; Akathisia, Drug-Induced; Haloperidol; Humans; Male; Middle Aged; Perphenazine; Propr	1994
[Effect of activation tasks on acute neuroleptic-induced akathisia]. Der Nervenarzt, 2000, Volume: 71, Issue:1 Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Arousal; Attention; Benperidol; Diagnosis, Dif	2000
Association of dopamine D3-receptor gene variants with neuroleptic induced akathisia in schizophrenic patients: a generalization of Steen's study on DRD3 and tardive dyskinesia. American journal of medical genetics, 2000, Apr-03, Volume: 96, Issue:2 Topics: Acute Disease; Akathisia, Drug-Induced; Amino Acid Substitution; Antipsychotic Agents; Dyskinesias;	2000
Prevalence and characteristics of patients with pseudoakathisia. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2000, Volume: 10, Issue:5 Topics: Adult; Akathisia, Drug-Induced; Antiparkinson Agents; Antipsychotic Agents; Chlorpromazine; Chronic	2000
Piracetam in the treatment of tardive dyskinesia and akathisia: a case report. Journal of clinical psychopharmacology, 2001, Volume: 21, Issue:2 Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Dyskinesia, Drug-Induced; Haloperidol; Humans;	2001
Mirtazapine for neuroleptic-induced akathisia. The American journal of psychiatry, 2001, Volume: 158, Issue:5 Topics: Adrenergic alpha-Antagonists; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Haloperidol; Hum	2001
[Treatment of delirium tremens with haloperidol (author's transl)]. Der Nervenarzt, 1978, Volume: 49, Issue:7 Topics: Adult; Akathisia, Drug-Induced; Alcohol Withdrawal Delirium; Dose-Response Relationship, Drug; Epile	1978
Haloperidol-induced dysphoria in patients with Tourette syndrome. The American journal of psychiatry, 1979, Volume: 136, Issue:9 Topics: Adolescent; Adult; Affect; Akathisia, Drug-Induced; Haloperidol; Humans; Male; Tourette Syndrome	1979
Neuroleptics. Violence as a manifestation of akathisia. JAMA, 1978, Nov-10, Volume: 240, Issue:20 Topics: Adult; Akathisia, Drug-Induced; Antisocial Personality Disorder; Haloperidol; Hostility; Humans; Imi	1978
Time course of D2-dopamine receptor occupancy examined by PET after single oral doses of haloperidol. Psychopharmacology, 1992, Volume: 106, Issue:4 Topics: Adult; Akathisia, Drug-Induced; Brain; Brain Chemistry; Haloperidol; Humans; Male; Prolactin; Psycho	1992
[Central anticholinergic intoxication syndrome. A contribution to the differential diagnosis of exogenous psychoses]. Deutsche medizinische Wochenschrift (1946), 1991, Nov-15, Volume: 116, Issue:46 Topics: Akathisia, Drug-Induced; Biperiden; Diagnosis, Differential; Doxepin; Dysarthria; Dyskinesia, Drug-I	1991
Akathisia: the syndrome of motor restlessness. American family physician, 1987, Volume: 35, Issue:2 Topics: Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Diphenhydramine; Haloperidol; Humans; Ma	1987
Subtle and underrecognized side effects of neuroleptic treatment in children with Tourette's disorder. The American journal of psychiatry, 1988, Volume: 145, Issue:5 Topics: Acute Disease; Adolescent; Aggression; Akathisia, Drug-Induced; Antipsychotic Agents; Child; Child,	1988
Tardive akathisia associated with low-dose haloperidol use. Journal of clinical psychopharmacology, 1987, Volume: 7, Issue:3 Topics: Akathisia, Drug-Induced; Female; Haloperidol; Humans; Middle Aged; Psychomotor Agitation	1987
A role for catecholamines in the pathogenesis of neuroleptic malignant syndrome. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 1986, Volume: 31, Issue:1 Topics: Akathisia, Drug-Induced; Brain Chemistry; Catecholamines; Chlorpromazine; Haloperidol; Humans; Imipr	1986
Suicide attempts associated with akathisia. The American journal of psychiatry, 1985, Volume: 142, Issue:4 Topics: Adult; Akathisia, Drug-Induced; Female; Fluphenazine; Haloperidol; Humans; Impulsive Behavior; Male;	1985
Successful treatment of neuroleptic-induced akathisia with baclofen and clonazepam. A case report. European neurology, 1985, Volume: 24, Issue:4 Topics: Akathisia, Drug-Induced; Baclofen; Benzodiazepinones; Clonazepam; Haloperidol; Humans; Male; Middle	1985

haloperidol and Acathisia, Drug-Induced